Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy), By Application (Diagnostics, Personalized Medicine), By Disease (Neurological Diseases, Cancer), By Region, And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 2 Business Days
Biomarkers Market Growth & Trends
The global biomarkers market size is expected to reach USD 181.03 billion by 2030, registering a CAGR of 13.3% over the forecast period, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.
The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.
These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.
The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company’s recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.
Biomarkers Market Report Highlights
Biomarkers Market Growth & Trends
The global biomarkers market size is expected to reach USD 181.03 billion by 2030, registering a CAGR of 13.3% over the forecast period, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.
The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.
These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.
The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company’s recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.
Biomarkers Market Report Highlights
- The safety segment held the largest share in 2022 owing to the increased adoption of safety biomarkers in drug discovery and development
- The efficacy segment will register the fastest growth rate from 2023 to 2030 due to a rise in strategic collaborations for promoting research activities
- The drug discovery & development segment accounted for the largest share in 2022 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
- The cancer disease segment dominated the industry in 2022. However, the neurological diseases segment is anticipated to record the fastest CAGRover the forecast years
- Asia Pacific is expected to be the fastest-growing region over the forecast period due to the rising investments by key players and increasing disease prevalence in the region
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Competitive Insights
CHAPTER 3 BIOMARKERS MARKET VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increasing funding for biomarkers
3.2.1.2 Increasing prevalence of chronic diseases
3.2.1.3 Technological advancements
3.2.2 Market restraint analysis
3.2.2.1 Lack of reimbursement policies for biomarkers treatment
3.3 Penetration & Growth Prospect Mapping
3.4 Influenza Vaccine: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
CHAPTER 4 BIOMARKERS MARKET SEGMENT ANALYSIS, BY TYPE, 2018-2030 (USD BILLION)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global Biomarkers Market, by Type, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Safety
4.5.1.1 Safety biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
4.5.2 Efficacy
4.5.2.1 Efficacy biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
4.5.3 Validation
4.5.3.1 Validation biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
CHAPTER 5 BIOMARKERS MARKET SEGMENT ANALYSIS, BY APPLICATION 2018-2030 (USD BILLION)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 Global Biomarkers Market, by Application, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Diagnostics
5.5.1.1 Diagnostics market estimates & forecasts, 2018 - 2030 (USD Billion)
5.5.2 Drug Discovery & Development
5.5.2.1 Drug discovery & development market estimates & forecasts, 2018 - 2030 (USD Billion)
5.5.3 Personalized Medicine
5.5.3.1 Personalized medicine market estimates & forecasts, 2018 - 2030 (USD Billion)
5.5.4 Others
5.5.4.1 Other applications market estimates & forecasts, 2018 - 2030 (USD Billion)
CHAPTER 6 BIOMARKERS MARKET SEGMENT ANALYSIS, BY DISEASE, 2018-2030 (USD BILLION)
6.1 Definition and Scope
6.2 Disease Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 Global Biomarkers Market, by Disease, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Cancer
6.5.1.1 Cancer biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.2 Cardiovascular Diseases
6.5.2.1 Cardiovascular disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.3 Neurological Diseases
6.5.3.1 Neurological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.4 Immunological Diseases
6.5.4.1 Immunological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.5 Others
6.5.5.1 Other diseases biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
CHAPTER 7 BIOMARKERS MARKET SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD BILLION)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East and Africa
7.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
7.6.1 North America
7.6.1.1 North America biomarkers market , 2018 - 2030 (USD Billion)
7.6.1.2 U.S.
7.6.1.2.1 Key Country Dynamics
7.6.1.2.2 Competitive Scenario
7.6.1.2.3 Regulatory Framework
7.6.1.2.4 Reimbursement Scenario
7.6.1.2.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.1.3 Canada
7.6.1.3.1 Key Country Dynamics
7.6.1.3.2 Competitive Scenario
7.6.1.3.3 Regulatory Framework
7.6.1.3.4 Reimbursement Scenario
7.6.1.3.5 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2 Europe
7.6.2.1 Europe biomarkers market, 2018 - 2030 (USD Billion)
7.6.2.2 U.K.
7.6.2.2.1 Key Country Dynamics
7.6.2.2.2 Competitive Scenario
7.6.2.2.3 Regulatory Framework
7.6.2.2.4 Reimbursement Scenario
7.6.2.2.5 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.3 Germany
7.6.2.3.1 Key Country Dynamics
7.6.2.3.2 Competitive Scenario
7.6.2.3.3 Regulatory Framework
7.6.2.23.4 Reimbursement Scenario
7.6.2.3.5 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.4 Spain
7.6.2.4.1 Key Country Dynamics
7.6.2.4.2 Competitive Scenario
7.6.2.4.3 Regulatory Framework
7.6.2.4.4 Reimbursement Scenario
7.6.2.4.5 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.5 France
7.6.2.5.1 Key Country Dynamics
7.6.2.5.2 Competitive Scenario
7.6.2.5.3 Regulatory Framework
7.6.2.5.4 Reimbursement Scenario
7.6.2.5.5 France market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.6 Italy
7.6.2.6.1 Key Country Dynamics
7.6.2.6.2 Competitive Scenario
7.6.2.6.3 Regulatory Framework
7.6.2.6.4 Reimbursement Scenario
7.6.2.6.5 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.7 Denmark
7.6.2.7.1 Key Country Dynamics
7.6.2.7.2 Competitive Scenario
7.6.2.7.3 Regulatory Framework
7.6.2.7.4 Reimbursement Scenario
7.6.2.7.5 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.8 Sweden
7.6.2.8.1 Key Country Dynamics
7.6.2.8.2 Competitive Scenario
7.6.2.8.3 Regulatory Framework
7.6.2.8.4 Reimbursement Scenario
7.6.2.8.5 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.9 Norway
7.6.2.9.1 Key Country Dynamics
7.6.2.9.2 Competitive Scenario
7.6.2.9.3 Regulatory Framework
7.6.2.9.4 Reimbursement Scenario
7.6.2.9.5 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3 Asia Pacific
7.6.3.1 Asia Pacific biomarkers market, 2018 - 2030 (USD Billion)
7.6.3.2 Japan
7.6.3.2.1 Key Country Dynamics
7.6.3.2.2 Competitive Scenario
7.6.3.2.3 Regulatory Framework
7.6.3.2.4 Reimbursement Scenario
7.6.3.2.5 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.3 China
7.6.3.3.1 Key Country Dynamics
7.6.3.3.2 Competitive Scenario
7.6.3.3.3 Regulatory Framework
7.6.3.3.4 Reimbursement Scenario
7.6.3.3.5 China market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.4 India
7.6.3.4.1 Key Country Dynamics
7.6.3.4.2 Competitive Scenario
7.6.3.4.3 Regulatory Framework
7.6.3.4.4 Reimbursement Scenario
7.6.3.4.5 India market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.5 South Korea
7.6.3.5.1 Key Country Dynamics
7.6.3.5.2 Competitive Scenario
7.6.3.5.3 Regulatory Framework
7.6.3.5.4 Reimbursement Scenario
7.6.3.25.5 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.6 Australia
7.6.3.6.1 Key Country Dynamics
7.6.3.6.2 Competitive Scenario
7.6.3.6.3 Regulatory Framework
7.6.3.6.4 Reimbursement Scenario
7.6.3.6.5 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.7 Thailand
7.6.3.7.1 Key Country Dynamics
7.6.3.7.2 Competitive Scenario
7.6.3.7.3 Regulatory Framework
7.6.3.7.4 Reimbursement Scenario
7.6.3.7.5 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.4 Latin America
7.6.4.1 Latin America biomarkers market, 2018 - 2030 (USD Billion)
7.6.4.2 Brazil
7.6.4.2.1 Key Country Dynamics
7.6.4.2.2 Competitive Scenario
7.6.4.2.3 Regulatory Framework
7.6.4.2.4 Reimbursement Scenario
7.6.4.2.5 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.4.3 Mexico
7.6.4.3.1 Key Country Dynamics
7.6.4.3.2 Competitive Scenario
7.6.4.3.3 Regulatory Framework
7.6.4.3.4 Reimbursement Scenario
7.6.4.3.5 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.4.4 Argentina
7.6.4.4.1 Key Country Dynamics
7.6.4.4.2 Competitive Scenario
7.6.4.4.3 Regulatory Framework
7.6.4.4.4 Reimbursement Scenario
7.6.4.4.5 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5 MEA
7.6.5.1 MEA biomarkers market, 2018 - 2030 (USD Billion)
7.6.5.2 South Africa
7.6.5.2.1 Key Country Dynamics
7.6.5.2.2 Competitive Scenario
7.6.5.2.3 Regulatory Framework
7.6.5.2.4 Reimbursement Scenario
7.6.5.2.5 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5.3 Saudi Arabia
7.6.5.3.1 Key Country Dynamics
7.6.5.3.2 Competitive Scenario
7.6.5.3.3 Regulatory Framework
7.6.5.3.4 Reimbursement Scenario
7.6.5.3.5 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5.4 UAE
7.6.5.4.1 Key Country Dynamics
7.6.5.4.2 Competitive Scenario
7.6.5.4.3 Regulatory Framework
7.6.5.4.4 Reimbursement Scenario
7.6.5.4.5 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5.5 Kuwait
7.6.5.5.1 Key Country Dynamics
7.6.5.5.2 Competitive Scenario
7.6.5.5.3 Regulatory Framework
7.6.5.5.4 Reimbursement Scenario
7.6.5.5.5 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 8 BIOMARKERS MARKET - COMPETITIVE ANALYSIS
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.1.2 Heat map analysis
8.1.3 Major Deals and Strategic Alliances Analysis
8.1.3.1 Joint Ventures
8.1.3.2 Licensing Agreements
8.1.3.3 Product Launches
8.1.3.1 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.4 Public Companies
8.4.1 Competitive Dashboard Analysis
8.4.1.1 Market Differentiators
8.5 Private Companies
8.5.1 List of key emerging companies
8.6 Company Profiles
8.6.1 F. Hoffmann-La Roche Ltd
8.6.1.1 Company overview
8.6.1.2 Financial performance
8.6.1.3 Product benchmarking
8.6.1.4 Strategic Initiatives
8.6.2 Abbott
8.6.2.1 Company overview
8.6.2.2 Financial performance
8.6.2.3 Product benchmarking
8.6.2.4 Strategic Initiatives
8.6.3 Epigenomics AG
8.6.3.1 Company overview
8.6.3.2 Financial performance
8.6.3.3 Product benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 General Electric
8.6.4.1 Company overview
8.6.4.2 Financial performance
8.6.4.3 Product benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 Johnson & Johnson Services, Inc.
8.6.5.1 Company overview
8.6.5.2 Financial performance
8.6.5.3 Product benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Thermo Fisher Scientific Inc.
8.6.6.1 Company overview
8.6.6.2 Financial performance
8.6.6.3 Product benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 Bio-Rad Laboratories, Inc.
8.6.7.1 Company overview
8.6.7.2 Financial performance
8.6.7.3 Product benchmarking
8.6.7.4 Strategic initiatives
8.6.8 Siemens Healthcare GmbH
8.6.8.1 Company overview
8.6.8.2 Financial performance
8.6.8.3 Product benchmarking
8.6.8.4 Strategic initiatives
8.6.9 QIAGEN
8.6.9.1 Company overview
8.6.9.2 Financial performance
8.6.9.3 Product benchmarking
8.6.9.4 Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Competitive Insights
CHAPTER 3 BIOMARKERS MARKET VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increasing funding for biomarkers
3.2.1.2 Increasing prevalence of chronic diseases
3.2.1.3 Technological advancements
3.2.2 Market restraint analysis
3.2.2.1 Lack of reimbursement policies for biomarkers treatment
3.3 Penetration & Growth Prospect Mapping
3.4 Influenza Vaccine: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
CHAPTER 4 BIOMARKERS MARKET SEGMENT ANALYSIS, BY TYPE, 2018-2030 (USD BILLION)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global Biomarkers Market, by Type, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Safety
4.5.1.1 Safety biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
4.5.2 Efficacy
4.5.2.1 Efficacy biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
4.5.3 Validation
4.5.3.1 Validation biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
CHAPTER 5 BIOMARKERS MARKET SEGMENT ANALYSIS, BY APPLICATION 2018-2030 (USD BILLION)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 Global Biomarkers Market, by Application, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Diagnostics
5.5.1.1 Diagnostics market estimates & forecasts, 2018 - 2030 (USD Billion)
5.5.2 Drug Discovery & Development
5.5.2.1 Drug discovery & development market estimates & forecasts, 2018 - 2030 (USD Billion)
5.5.3 Personalized Medicine
5.5.3.1 Personalized medicine market estimates & forecasts, 2018 - 2030 (USD Billion)
5.5.4 Others
5.5.4.1 Other applications market estimates & forecasts, 2018 - 2030 (USD Billion)
CHAPTER 6 BIOMARKERS MARKET SEGMENT ANALYSIS, BY DISEASE, 2018-2030 (USD BILLION)
6.1 Definition and Scope
6.2 Disease Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 Global Biomarkers Market, by Disease, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Cancer
6.5.1.1 Cancer biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.2 Cardiovascular Diseases
6.5.2.1 Cardiovascular disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.3 Neurological Diseases
6.5.3.1 Neurological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.4 Immunological Diseases
6.5.4.1 Immunological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
6.5.5 Others
6.5.5.1 Other diseases biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
CHAPTER 7 BIOMARKERS MARKET SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD BILLION)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East and Africa
7.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
7.6.1 North America
7.6.1.1 North America biomarkers market , 2018 - 2030 (USD Billion)
7.6.1.2 U.S.
7.6.1.2.1 Key Country Dynamics
7.6.1.2.2 Competitive Scenario
7.6.1.2.3 Regulatory Framework
7.6.1.2.4 Reimbursement Scenario
7.6.1.2.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.1.3 Canada
7.6.1.3.1 Key Country Dynamics
7.6.1.3.2 Competitive Scenario
7.6.1.3.3 Regulatory Framework
7.6.1.3.4 Reimbursement Scenario
7.6.1.3.5 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2 Europe
7.6.2.1 Europe biomarkers market, 2018 - 2030 (USD Billion)
7.6.2.2 U.K.
7.6.2.2.1 Key Country Dynamics
7.6.2.2.2 Competitive Scenario
7.6.2.2.3 Regulatory Framework
7.6.2.2.4 Reimbursement Scenario
7.6.2.2.5 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.3 Germany
7.6.2.3.1 Key Country Dynamics
7.6.2.3.2 Competitive Scenario
7.6.2.3.3 Regulatory Framework
7.6.2.23.4 Reimbursement Scenario
7.6.2.3.5 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.4 Spain
7.6.2.4.1 Key Country Dynamics
7.6.2.4.2 Competitive Scenario
7.6.2.4.3 Regulatory Framework
7.6.2.4.4 Reimbursement Scenario
7.6.2.4.5 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.5 France
7.6.2.5.1 Key Country Dynamics
7.6.2.5.2 Competitive Scenario
7.6.2.5.3 Regulatory Framework
7.6.2.5.4 Reimbursement Scenario
7.6.2.5.5 France market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.6 Italy
7.6.2.6.1 Key Country Dynamics
7.6.2.6.2 Competitive Scenario
7.6.2.6.3 Regulatory Framework
7.6.2.6.4 Reimbursement Scenario
7.6.2.6.5 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.7 Denmark
7.6.2.7.1 Key Country Dynamics
7.6.2.7.2 Competitive Scenario
7.6.2.7.3 Regulatory Framework
7.6.2.7.4 Reimbursement Scenario
7.6.2.7.5 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.8 Sweden
7.6.2.8.1 Key Country Dynamics
7.6.2.8.2 Competitive Scenario
7.6.2.8.3 Regulatory Framework
7.6.2.8.4 Reimbursement Scenario
7.6.2.8.5 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.2.9 Norway
7.6.2.9.1 Key Country Dynamics
7.6.2.9.2 Competitive Scenario
7.6.2.9.3 Regulatory Framework
7.6.2.9.4 Reimbursement Scenario
7.6.2.9.5 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3 Asia Pacific
7.6.3.1 Asia Pacific biomarkers market, 2018 - 2030 (USD Billion)
7.6.3.2 Japan
7.6.3.2.1 Key Country Dynamics
7.6.3.2.2 Competitive Scenario
7.6.3.2.3 Regulatory Framework
7.6.3.2.4 Reimbursement Scenario
7.6.3.2.5 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.3 China
7.6.3.3.1 Key Country Dynamics
7.6.3.3.2 Competitive Scenario
7.6.3.3.3 Regulatory Framework
7.6.3.3.4 Reimbursement Scenario
7.6.3.3.5 China market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.4 India
7.6.3.4.1 Key Country Dynamics
7.6.3.4.2 Competitive Scenario
7.6.3.4.3 Regulatory Framework
7.6.3.4.4 Reimbursement Scenario
7.6.3.4.5 India market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.5 South Korea
7.6.3.5.1 Key Country Dynamics
7.6.3.5.2 Competitive Scenario
7.6.3.5.3 Regulatory Framework
7.6.3.5.4 Reimbursement Scenario
7.6.3.25.5 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.6 Australia
7.6.3.6.1 Key Country Dynamics
7.6.3.6.2 Competitive Scenario
7.6.3.6.3 Regulatory Framework
7.6.3.6.4 Reimbursement Scenario
7.6.3.6.5 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.3.7 Thailand
7.6.3.7.1 Key Country Dynamics
7.6.3.7.2 Competitive Scenario
7.6.3.7.3 Regulatory Framework
7.6.3.7.4 Reimbursement Scenario
7.6.3.7.5 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.4 Latin America
7.6.4.1 Latin America biomarkers market, 2018 - 2030 (USD Billion)
7.6.4.2 Brazil
7.6.4.2.1 Key Country Dynamics
7.6.4.2.2 Competitive Scenario
7.6.4.2.3 Regulatory Framework
7.6.4.2.4 Reimbursement Scenario
7.6.4.2.5 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.4.3 Mexico
7.6.4.3.1 Key Country Dynamics
7.6.4.3.2 Competitive Scenario
7.6.4.3.3 Regulatory Framework
7.6.4.3.4 Reimbursement Scenario
7.6.4.3.5 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.4.4 Argentina
7.6.4.4.1 Key Country Dynamics
7.6.4.4.2 Competitive Scenario
7.6.4.4.3 Regulatory Framework
7.6.4.4.4 Reimbursement Scenario
7.6.4.4.5 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5 MEA
7.6.5.1 MEA biomarkers market, 2018 - 2030 (USD Billion)
7.6.5.2 South Africa
7.6.5.2.1 Key Country Dynamics
7.6.5.2.2 Competitive Scenario
7.6.5.2.3 Regulatory Framework
7.6.5.2.4 Reimbursement Scenario
7.6.5.2.5 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5.3 Saudi Arabia
7.6.5.3.1 Key Country Dynamics
7.6.5.3.2 Competitive Scenario
7.6.5.3.3 Regulatory Framework
7.6.5.3.4 Reimbursement Scenario
7.6.5.3.5 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5.4 UAE
7.6.5.4.1 Key Country Dynamics
7.6.5.4.2 Competitive Scenario
7.6.5.4.3 Regulatory Framework
7.6.5.4.4 Reimbursement Scenario
7.6.5.4.5 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
7.6.5.5 Kuwait
7.6.5.5.1 Key Country Dynamics
7.6.5.5.2 Competitive Scenario
7.6.5.5.3 Regulatory Framework
7.6.5.5.4 Reimbursement Scenario
7.6.5.5.5 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 8 BIOMARKERS MARKET - COMPETITIVE ANALYSIS
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.1.2 Heat map analysis
8.1.3 Major Deals and Strategic Alliances Analysis
8.1.3.1 Joint Ventures
8.1.3.2 Licensing Agreements
8.1.3.3 Product Launches
8.1.3.1 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.4 Public Companies
8.4.1 Competitive Dashboard Analysis
8.4.1.1 Market Differentiators
8.5 Private Companies
8.5.1 List of key emerging companies
8.6 Company Profiles
8.6.1 F. Hoffmann-La Roche Ltd
8.6.1.1 Company overview
8.6.1.2 Financial performance
8.6.1.3 Product benchmarking
8.6.1.4 Strategic Initiatives
8.6.2 Abbott
8.6.2.1 Company overview
8.6.2.2 Financial performance
8.6.2.3 Product benchmarking
8.6.2.4 Strategic Initiatives
8.6.3 Epigenomics AG
8.6.3.1 Company overview
8.6.3.2 Financial performance
8.6.3.3 Product benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 General Electric
8.6.4.1 Company overview
8.6.4.2 Financial performance
8.6.4.3 Product benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 Johnson & Johnson Services, Inc.
8.6.5.1 Company overview
8.6.5.2 Financial performance
8.6.5.3 Product benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Thermo Fisher Scientific Inc.
8.6.6.1 Company overview
8.6.6.2 Financial performance
8.6.6.3 Product benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 Bio-Rad Laboratories, Inc.
8.6.7.1 Company overview
8.6.7.2 Financial performance
8.6.7.3 Product benchmarking
8.6.7.4 Strategic initiatives
8.6.8 Siemens Healthcare GmbH
8.6.8.1 Company overview
8.6.8.2 Financial performance
8.6.8.3 Product benchmarking
8.6.8.4 Strategic initiatives
8.6.9 QIAGEN
8.6.9.1 Company overview
8.6.9.2 Financial performance
8.6.9.3 Product benchmarking
8.6.9.4 Strategic initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global Biomarkers Market, By Region, 2018 - 2030 (USD Billion)
Table 5 Global Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 6 Global Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 7 Global Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 8 North America Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 9 North America Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 10 North America Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 11 North America Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 12 U.S. Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 13 U.S. Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 14 U.S. Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 15 Canada Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 16 Canada Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 17 Canada Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 18 Europe Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 19 Europe Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 20 Europe Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 21 Europe Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 22 Germany Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 23 Germany Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 24 Germany Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 25 U.K. Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 26 U.K. Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 27 U.K. Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 28 France Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 29 France Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 30 France Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 31 Spain Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 32 Spain Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 33 Spain Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 34 Italy Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 35 Italy Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 36 Italy Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 37 Denmark Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 38 Denmark Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 39 Denmark Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 40 Norway Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 41 Norway Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 42 Norway Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 43 Sweden Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 44 Sweden Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 45 Sweden Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 46 Asia Pacific Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 47 Asia Pacific Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 48 Asia Pacific Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 49 Asia Pacific Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 50 Japan Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 51 Japan Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 52 Japan Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 53 China Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 54 China Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 55 China Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 56 India Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 57 India Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 58 India Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 59 South Korea Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 60 South Korea Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 61 South Korea Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 62 Australia Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 63 Australia Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 64 Australia Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 65 Thailand Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 66 Thailand Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 67 Thailand Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 68 Latin America Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 69 Latin America Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 70 Latin America Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 71 Latin America Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 72 Brazil Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 73 Brazil Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 74 Brazil Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 75 Argentina Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 76 Argentina Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 77 Argentina Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 78 Mexico Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 79 Mexico Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 80 Mexico Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 81 Middle East and Africa Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 82 Middle East and Africa Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 83 Middle East and Africa Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 84 Middle East and Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 85 South Africa Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 86 South Africa Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 87 South Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 88 Saudi Arabia Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 89 Saudi Arabia Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 90 Saudi Arabia Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 91 Kuwait Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 92 Kuwait Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 93 Kuwait Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 94 UAE Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 95 UAE Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 96 UAE Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global Biomarkers Market, By Region, 2018 - 2030 (USD Billion)
Table 5 Global Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 6 Global Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 7 Global Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 8 North America Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 9 North America Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 10 North America Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 11 North America Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 12 U.S. Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 13 U.S. Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 14 U.S. Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 15 Canada Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 16 Canada Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 17 Canada Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 18 Europe Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 19 Europe Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 20 Europe Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 21 Europe Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 22 Germany Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 23 Germany Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 24 Germany Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 25 U.K. Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 26 U.K. Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 27 U.K. Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 28 France Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 29 France Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 30 France Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 31 Spain Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 32 Spain Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 33 Spain Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 34 Italy Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 35 Italy Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 36 Italy Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 37 Denmark Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 38 Denmark Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 39 Denmark Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 40 Norway Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 41 Norway Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 42 Norway Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 43 Sweden Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 44 Sweden Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 45 Sweden Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 46 Asia Pacific Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 47 Asia Pacific Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 48 Asia Pacific Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 49 Asia Pacific Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 50 Japan Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 51 Japan Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 52 Japan Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 53 China Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 54 China Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 55 China Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 56 India Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 57 India Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 58 India Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 59 South Korea Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 60 South Korea Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 61 South Korea Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 62 Australia Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 63 Australia Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 64 Australia Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 65 Thailand Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 66 Thailand Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 67 Thailand Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 68 Latin America Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 69 Latin America Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 70 Latin America Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 71 Latin America Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 72 Brazil Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 73 Brazil Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 74 Brazil Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 75 Argentina Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 76 Argentina Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 77 Argentina Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 78 Mexico Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 79 Mexico Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 80 Mexico Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 81 Middle East and Africa Biomarkers Market, By Country, 2018 - 2030 (USD Billion)
Table 82 Middle East and Africa Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 83 Middle East and Africa Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 84 Middle East and Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 85 South Africa Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 86 South Africa Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 87 South Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 88 Saudi Arabia Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 89 Saudi Arabia Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 90 Saudi Arabia Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 91 Kuwait Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 92 Kuwait Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 93 Kuwait Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
Table 94 UAE Biomarkers Market, By Type, 2018 - 2030 (USD Billion)
Table 95 UAE Biomarkers Market, By Application, 2018 - 2030 (USD Billion)
Table 96 UAE Biomarkers Market, By Disease, 2018 - 2030 (USD Billion)
LIST OF FIGURES
Fig. 1 Biomarkers market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot (2022) (USD billion)
Fig. 10 Segment snapshot (2022) (USD billion)
Fig. 11 Competitive Insights
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Consumer behavior analysis
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 PESTLE analysis
Fig. 18 Strategy mapping
Fig. 19 Biomarkers market: Type movement analysis
Fig. 20 Type segment dashboard
Fig. 21 Biomarkers market type outlook: Key takeaways
Fig. 22 Safety biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 23 Efficacy biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 24 Validation biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 25 Biomarkers market: Application movement analysis
Fig. 26 Application segment dashboard
Fig. 27 Biomarkers market application outlook: Key takeaways
Fig. 28 Diagnostics market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 29 Drug discovery & development market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 30 Personalized market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 31 Other applications market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 32 Biomarkers market: Diseases movement analysis
Fig. 33 Diseases segment dashboard
Fig. 34 Biomarkers market diseases outlook: Key takeaways
Fig. 35 Cancer biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 36 Cardiovascular disease biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 37 Neurological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 38 Immunological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 39 Other diseases biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 40 Regional marketplace: Key takeaways
Fig. 41 Regional marketplace: Key takeaways (continued)
Fig. 42 North America: SWOT analysis
Fig. 43 North America biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 44 Key country dynamics
Fig. 45 Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 46 U.S. biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 47 Key country dynamics
Fig. 48 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 49 Canada biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 50 Europe: SWOT analysis
Fig. 51 Europe biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 52 Key country dynamics
Fig. 53 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 54 Germany biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 55 Key country dynamics
Fig. 56 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 57 U.K. biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 58 Key country dynamics
Fig. 59 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 60 France biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 61 Key country dynamics
Fig. 62 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 63 Italy biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 64 Key country dynamics
Fig. 65 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 66 Spain biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 67 Key country dynamics
Fig. 68 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 69 Denmark biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 70 Key country dynamics
Fig. 71 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 72 Sweden biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 73 Key country dynamics
Fig. 74 Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 75 Norway biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 76 Rest of Europe biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 77 Asia Pacific: SWOT analysis
Fig. 78 Asia Pacific biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 79 Key country dynamics
Fig. 80 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 81 Japan biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 82 Key country dynamics
Fig. 83 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 84 China biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 85 Key country dynamics
Fig. 86 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 87 India biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 88 Key country dynamics
Fig. 89 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 90 South Korea biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 91 Key country dynamics
Fig. 92 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 93 Australia biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 94 Key country dynamics
Fig. 95 Target disease prevalence, 2022, (%)
Fig. 96 Thailand biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 97 Rest of Asia Pacific biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 98 Latin America: SWOT analysis
Fig. 99 Latin America biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 100 Key country dynamics
Fig. 101 Target disease prevalence, 2022 (%)
Fig. 102 Brazil biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 103 Key country dynamics
Fig. 104 Target disease prevalence, 2022 (%)
Fig. 105 Mexico biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 106 Key country dynamics
Fig. 107 Target disease prevalence, 2022 (%)
Fig. 108 Argentina biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 109 Argentina biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 110 MEA: SWOT analysis
Fig. 111 Middle East & Africa biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 112 Key country dynamics
Fig. 113 Target disease prevalence, 2022 (%)
Fig. 114 South Africa biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 115 Key country dynamics
Fig. 116 Target disease prevalence, 2022 (%)
Fig. 117 Saudi Arabia biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 118 Key country dynamics
Fig. 119 Target disease prevalence, 2022 (%)
Fig. 120 UAE biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 121 Key country dynamics
Fig. 122 Target disease prevalence, 2022 (%)
Fig. 123 Kuwait biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 124 Rest of MEA biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 125 Ansoff Matrix
Fig. 126 Heat map analysis
Fig. 127 Company market share analysis
Fig. 128 Company market position analysis (2022)
Fig. 129 Company market position analysis (2022)
Fig. 130 Market differentiators
Fig. 1 Biomarkers market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot (2022) (USD billion)
Fig. 10 Segment snapshot (2022) (USD billion)
Fig. 11 Competitive Insights
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Consumer behavior analysis
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 PESTLE analysis
Fig. 18 Strategy mapping
Fig. 19 Biomarkers market: Type movement analysis
Fig. 20 Type segment dashboard
Fig. 21 Biomarkers market type outlook: Key takeaways
Fig. 22 Safety biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 23 Efficacy biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 24 Validation biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 25 Biomarkers market: Application movement analysis
Fig. 26 Application segment dashboard
Fig. 27 Biomarkers market application outlook: Key takeaways
Fig. 28 Diagnostics market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 29 Drug discovery & development market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 30 Personalized market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 31 Other applications market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 32 Biomarkers market: Diseases movement analysis
Fig. 33 Diseases segment dashboard
Fig. 34 Biomarkers market diseases outlook: Key takeaways
Fig. 35 Cancer biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 36 Cardiovascular disease biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 37 Neurological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 38 Immunological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 39 Other diseases biomarkers market estimates & forecasts, 2018 - 2030 (USD billion)
Fig. 40 Regional marketplace: Key takeaways
Fig. 41 Regional marketplace: Key takeaways (continued)
Fig. 42 North America: SWOT analysis
Fig. 43 North America biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 44 Key country dynamics
Fig. 45 Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 46 U.S. biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 47 Key country dynamics
Fig. 48 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 49 Canada biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 50 Europe: SWOT analysis
Fig. 51 Europe biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 52 Key country dynamics
Fig. 53 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 54 Germany biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 55 Key country dynamics
Fig. 56 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 57 U.K. biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 58 Key country dynamics
Fig. 59 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 60 France biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 61 Key country dynamics
Fig. 62 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 63 Italy biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 64 Key country dynamics
Fig. 65 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 66 Spain biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 67 Key country dynamics
Fig. 68 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 69 Denmark biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 70 Key country dynamics
Fig. 71 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 72 Sweden biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 73 Key country dynamics
Fig. 74 Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 75 Norway biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 76 Rest of Europe biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 77 Asia Pacific: SWOT analysis
Fig. 78 Asia Pacific biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 79 Key country dynamics
Fig. 80 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 81 Japan biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 82 Key country dynamics
Fig. 83 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 84 China biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 85 Key country dynamics
Fig. 86 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 87 India biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 88 Key country dynamics
Fig. 89 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 90 South Korea biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 91 Key country dynamics
Fig. 92 Target disease prevalence (patient volume) ('000), 2018 - 2030
Fig. 93 Australia biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 94 Key country dynamics
Fig. 95 Target disease prevalence, 2022, (%)
Fig. 96 Thailand biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 97 Rest of Asia Pacific biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 98 Latin America: SWOT analysis
Fig. 99 Latin America biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 100 Key country dynamics
Fig. 101 Target disease prevalence, 2022 (%)
Fig. 102 Brazil biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 103 Key country dynamics
Fig. 104 Target disease prevalence, 2022 (%)
Fig. 105 Mexico biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 106 Key country dynamics
Fig. 107 Target disease prevalence, 2022 (%)
Fig. 108 Argentina biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 109 Argentina biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 110 MEA: SWOT analysis
Fig. 111 Middle East & Africa biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 112 Key country dynamics
Fig. 113 Target disease prevalence, 2022 (%)
Fig. 114 South Africa biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 115 Key country dynamics
Fig. 116 Target disease prevalence, 2022 (%)
Fig. 117 Saudi Arabia biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 118 Key country dynamics
Fig. 119 Target disease prevalence, 2022 (%)
Fig. 120 UAE biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 121 Key country dynamics
Fig. 122 Target disease prevalence, 2022 (%)
Fig. 123 Kuwait biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 124 Rest of MEA biomarkers market estimates and forecasts, 2018 - 2030 (USD billion)
Fig. 125 Ansoff Matrix
Fig. 126 Heat map analysis
Fig. 127 Company market share analysis
Fig. 128 Company market position analysis (2022)
Fig. 129 Company market position analysis (2022)
Fig. 130 Market differentiators
